BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 38440727)

  • 1. Neoadjuvant Immune Checkpoint Inhibitors in hepatocellular carcinoma: a meta-analysis and systematic review.
    Tian C; Yu Y; Wang Y; Yang L; Tang Y; Yu C; Feng G; Zheng D; Wang X
    Front Immunol; 2024; 15():1352873. PubMed ID: 38440727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant immunotherapy for resectable hepatocellular carcinoma: a systematic review and meta-analysis.
    Han YH; Bo JQ; Liu LX
    Eur Rev Med Pharmacol Sci; 2023 Aug; 27(15):7134-7147. PubMed ID: 37606124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant Immune Checkpoint Inhibitors for Resectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
    Zhao M; Chen S; Li C; Du Y; Li P
    Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Clinical and Safety Outcomes of Neoadjuvant Immunotherapy Combined With Chemotherapy for Patients With Resectable Esophageal Cancer: A Systematic Review and Meta-analysis.
    Ge F; Huo Z; Cai X; Hu Q; Chen W; Lin G; Zhong R; You Z; Wang R; Lu Y; Wang R; Huang Q; Zhang H; Song A; Li C; Wen Y; Jiang Y; Liang H; He J; Liang W; Liu J
    JAMA Netw Open; 2022 Nov; 5(11):e2239778. PubMed ID: 36322089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy followed by adjuvant immunotherapy in resectable non-small cell lung cancer: a meta-analysis of phase 3 clinical trials.
    Zhang W; Liang Z; Zhao Y; Li Y; Chen T; Li W; Chen Y; Wu P; Zhang H; Fang C; Li L
    Front Immunol; 2024; 15():1359302. PubMed ID: 38646542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant PD-1/PD-L1 Inhibitors for Resectable Head and Neck Cancer: A Systematic Review and Meta-analysis.
    Masarwy R; Kampel L; Horowitz G; Gutfeld O; Muhanna N
    JAMA Otolaryngol Head Neck Surg; 2021 Oct; 147(10):871-878. PubMed ID: 34473219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Meta-analysis.
    Jácome AA; Castro ACG; Vasconcelos JPS; Silva MHCR; Lessa MAO; Moraes ED; Andrade AC; Lima FMT; Farias JPF; Gil RA; Prolla G; Garicochea B
    JAMA Netw Open; 2021 Dec; 4(12):e2136128. PubMed ID: 34870682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of neoadjuvant immunotherapy in resectable gastric/gastroesophageal junction tumors: a meta-analysis and systematic review.
    Wang J; Tong T; Zhang G; Jin C; Guo H; Liu X; Zhang Z; Li J; Zhao Y
    Front Immunol; 2024; 15():1339757. PubMed ID: 38352873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of combined targeted therapy and immunotherapy versus targeted monotherapy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
    Yang TK; Yu YF; Tsai CL; Li HJ; Yang PS; Huang KW; Cheng JC
    BMC Cancer; 2022 Oct; 22(1):1085. PubMed ID: 36271374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review.
    Ulas EB; Dickhoff C; Schneiders FL; Senan S; Bahce I
    ESMO Open; 2021 Oct; 6(5):100244. PubMed ID: 34479033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viral Status and Efficacy of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis.
    Ding Z; Dong Z; Chen Z; Hong J; Yan L; Li H; Yao S; Yan Y; Yang Y; Yang C; Li T
    Front Immunol; 2021; 12():733530. PubMed ID: 34659220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of neoadjuvant immunotherapy in resectable locally advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis.
    He W; Wang C; Li C; Nie X; Li H; Li J; Zhao N; Chen H; Miao X; Han Y; Peng L; Leng X
    Front Immunol; 2023; 14():1118902. PubMed ID: 36875107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
    Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
    Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC: An Indirect Meta-Analysis.
    Zhou Y; Li A; Yu H; Wang Y; Zhang X; Qiu H; Du W; Luo L; Fu S; Zhang L; Hong S
    JAMA Netw Open; 2024 Mar; 7(3):e241285. PubMed ID: 38451524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of neoadjuvant immunotherapy versus routine neoadjuvant therapy for patients with locally advanced esophageal cancer: A systematic review and meta-analysis.
    Qin H; Liu F; Zhang Y; Liang Y; Mi Y; Yu F; Xu H; Li K; Lin C; Li L; Tian Z; Wang L
    Front Immunol; 2023; 14():1108213. PubMed ID: 37033991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of neoadjuvant immunotherapy in resectable nonsmall cell lung cancer: A meta-analysis.
    Jia XH; Xu H; Geng LY; Jiao M; Wang WJ; Jiang LL; Guo H
    Lung Cancer; 2020 Sep; 147():143-153. PubMed ID: 32717571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple combination of HAIC-FO plus tyrosine kinase inhibitors and immune checkpoint inhibitors for advanced hepatocellular carcinoma: A systematic review and meta-analysis.
    Tan Z; Zhang J; Xu L; Wang H; Mao X; Zou R; Wang Q; Han Z; Di Z; Wu D
    PLoS One; 2023; 18(10):e0290644. PubMed ID: 37844117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis.
    Rao Q; Li M; Xu W; Pang K; Guo X; Wang D; Liu J; Guo W; Zhang Z
    Hepatol Int; 2020 Sep; 14(5):765-775. PubMed ID: 32572818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Neoadjuvant Therapy Prior to Curative Resection in Hepatocellular Carcinoma.
    Whitham Z; Hsiehchen D
    Surg Oncol Clin N Am; 2024 Jan; 33(1):87-97. PubMed ID: 37945147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint inhibitors in neoadjuvant therapy of non-small cell lung cancer: a systematic review and meta-analysis.
    Ge S; Huang C
    J Thorac Dis; 2022 Feb; 14(2):333-342. PubMed ID: 35280480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.